Health Robotics Publishes its 572 European Gravimetric Drug Vial Database for its Sterile Compounding Robots

News provided by

Health Robotics

25 Jul, 2013, 12:00 GMT

BOZEN, Sud-Tirol, Italy, July 25, 2013 /PRNewswire/ --

Health Robotics recently released to the pharmacy community at large, its European Database[1] of 572 supported and "Live" drug vials for Automated Sterile Compounding, corresponding to 213 active pharmaceutical ingredients [170 for chemotherapy, 35 non-hazardous, and 8 mAbs], including supported drug brands, available vial sizes, and drug vial concentrations from 102 drug manufacturers.

Gaspar DeViedma, Health Robotics' Executive Vice President stated: "We have now publicly released both the American and European gravimetric databases [website registration required], developed in cooperation with our customers and the support of the drug manufacturing industry, and which are currently used by our "Live" customers in our two primary markets of Europe and North America."

Health Robotics' combined gravimetric databases of 902 drug vials with 345 active pharmaceutical ingredients from 160 drug manufacturers represent by far the largest IV Automation gravimetric-control database ever published in the world, outpacing our combined competitors[2] by a factor of at least 20 to 1. Double-Checks and Gravimetric Control (weight-based) are at the heart of the unique Patient Safety Systems developed by Health Robotics, which provides the world's only integrated Robotic and Non-Robotic [manual compounding] IV Automation.

Mr. DeViedma continued: "Health Robotics offers these unique drug vial databases at no cost to its worldwide customers and global distributors. Customers and distributors are able to access the individual drug vial densities by signing a waiver with Health Robotics. This proven methodology has exponentially expanded the utilization of Health Robotics' Sterile Compounding Automation solutions from the original 30+ drug vials in 2007 to the current 900+ vials, and growing every month."

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing almost 500 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies[3],[4],[5]] to greatly contribute to ease hospitals' growing pressures to improve patient safety[3], increase throughput, and contain costs[3]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug[3] and diluent[3] exchange errors, improve drug potency[4], decrease other medical mistakes and sterility risks, work more efficiently[3], reduce waste and controlled substances' diversion, reduce pharmacy technician upper-limb injuries[5], and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff. For more information, please visit: http://www.health-robotics.com

--------------------------------------------------

1. http://www.health-robotics.com/en/solutions/drugdatabases

2. Baxter-IntelliFill, Fresenius-MDS, Intelligent Hospital Systems-RIVA, Loccioni-Apoteca

3. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

4. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

5. Comparing the upper limb disorder risks associated with manual and automated cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin, Dean, Franklin. Imperial College Healthcare NHS Trust. European Journal of Hospital Pharmacy April 2012.

For additional information, please contact:

Luisa Celeghin
celeghin@health-robotics.com
+39-(0)403-498-468